Mimedx Group, Inc. (MDXG) — SEC Filings
Mimedx Group, Inc. (MDXG) — 33 SEC filings. Latest: 8-K (Apr 16, 2026). Includes 17 8-K, 6 SC 13G/A, 5 10-Q.
View Mimedx Group, Inc. on SEC EDGAR
Overview
Mimedx Group, Inc. (MDXG) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 29, 2025: MIMEDX GROUP, INC. (MDXG) reported a significant increase in net sales and net income for the three and nine months ended September 30, 2025. Net sales for the three months ended September 30, 2025, surged to $113.7 million, up from $84.1 million in the prior year, representing a 35.2% increase. Net
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 1 bullish, 31 neutral, 1 mixed. The dominant filing sentiment for Mimedx Group, Inc. is neutral.
Filing Type Overview
Mimedx Group, Inc. (MDXG) has filed 17 8-K, 5 10-Q, 1 DEFA14A, 2 10-K, 6 SC 13G/A, 1 SC 13G, 1 DEF 14A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of MDXG's 22 recent filings, 0 were flagged as high-risk, 7 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $113.7M |
| Net Income | $16.7M |
| EPS | $0.11 |
| Debt-to-Equity | 0.07 |
| Cash Position | $142.1M |
| Operating Margin | 19.5% |
| Total Assets | $319.0M |
| Total Debt | $18.2M |
Key Executives
- Dr. Christopher J. Weber
- Dr. Michael J. DeGeorge
- Ms. Karen L. King
- Mr. William D. Inc.
Industry Context
MIMEDX GROUP operates in the regenerative medicine and biologics sector, focusing on advanced wound care, burn treatment, and surgical applications. The industry is characterized by significant R&D investment, stringent regulatory oversight (FDA), and a competitive landscape with both established players and emerging biotech firms. Growth is driven by an aging population, increasing prevalence of chronic diseases, and advancements in regenerative therapies.
Top Tags
regulation-fd (4) · 10-Q (4) · financials (4) · disclosure (3) · sec-filing (3) · corporate-filing (3) · Healthcare (2) · corporate-governance (2) · shareholder-vote (2) · reporting (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Sales (Q3 2025) | $113.7M | Increased 35.2% from $84.1M in Q3 2024 |
| Net Income (Q3 2025) | $16.7M | More than doubled from $8.1M in Q3 2024 |
| Net Sales (YTD 2025) | $300.5M | Increased 17.4% from $256.0M in YTD 2024 |
| Cash and Cash Equivalents | $142.1M | Increased from $104.4M at Dec 31, 2024 |
| Accounts Receivable, Net | $78.2M | Increased from $55.8M at Dec 31, 2024, indicating potential collection risk |
| Credit Loss Expense (YTD 2025) | $3.1M | Significantly increased from $0.1M in YTD 2024 |
| Common Shares Outstanding | 148,102,159 | As of October 20, 2025 |
| Total Stockholders' Equity | $238.9M | Increased from $193.1M at Dec 31, 2024 |
| Net Cash Flows from Operating Activities (YTD 2025) | $49.0M | Slightly increased from $47.4M in YTD 2024 |
| Accumulated Deficit | $57.9M | Reduced from $91.3M at Dec 31, 2024, indicating improved profitability |
| Period End Date | 2025-03-31 | Reporting period for the 10-Q |
| Filing Date | 2025-04-30 | Date the report was submitted to the SEC |
| SIC Code | 3841 | Standard Industrial Classification for Surgical & Medical Instruments & Apparatus |
| Fiscal Year | 2024 | Reporting period |
| Previous Fiscal Year | 2023 | Comparison period |
Frequently Asked Questions
What are the latest SEC filings for Mimedx Group, Inc. (MDXG)?
Mimedx Group, Inc. has 33 recent SEC filings from Jan 2024 to Apr 2026, including 17 8-K, 6 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MDXG filings?
Across 33 filings, the sentiment breakdown is: 1 bullish, 31 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Mimedx Group, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Mimedx Group, Inc. (MDXG) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Mimedx Group, Inc.?
Key financial highlights from Mimedx Group, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MDXG?
The investment thesis for MDXG includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Mimedx Group, Inc.?
Key executives identified across Mimedx Group, Inc.'s filings include Dr. Christopher J. Weber, Dr. Michael J. DeGeorge, Ms. Karen L. King, Mr. William D. Inc..
What are the main risk factors for Mimedx Group, Inc. stock?
Of MDXG's 22 assessed filings, 0 were flagged high-risk, 7 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Mimedx Group, Inc.?
Forward guidance and predictions for Mimedx Group, Inc. are extracted from SEC filings as they are enriched.